| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.75▼ | 0.74▲ | 0.74▲ | 0.70▲ | 2.30▼ |
| MA10 | 0.74▲ | 0.75▼ | 0.76▼ | 0.71▲ | 6.05▼ |
| MA20 | 0.75▼ | 0.75▼ | 0.73▲ | 2.06▼ | 23.74▼ |
| MA50 | 0.77▼ | 0.68▲ | 0.69▲ | 7.49▼ | 83.40▼ |
| MA100 | 0.72▲ | 0.72▲ | 0.68▲ | 29.21▼ | N/A |
| MA200 | 0.67▲ | 0.88▼ | 4.30▼ | 59.25▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | -0.007▼ | 0.000▼ | 0.559▲ | 4.763▲ |
| RSI | 45.251▼ | 52.494▲ | 53.269▲ | 24.771▼ | 30.511▼ |
| STOCH | 71.945 | 29.338 | 35.470 | 27.647 | 2.425▼ |
| WILL %R | -28.016 | -69.472 | -59.674 | -62.766 | -99.312▼ |
| CCI | -2.825 | -57.317 | -7.521 | 45.712 | -77.218 |
|
Monday, March 17, 2025 05:00 PM
IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/03/25 | 0.71 | 0.767 | 0.69 | 0.75 | 570,563 |
| 18/03/25 | 0.7322 | 0.8481 | 0.6817 | 0.75 | 956,078 |
| 17/03/25 | 0.6642 | 0.7345 | 0.615 | 0.73 | 998,560 |
| 14/03/25 | 0.6057 | 0.668 | 0.589 | 0.6615 | 932,181 |
| 13/03/25 | 0.64 | 0.64 | 0.55 | 0.601 | 1,656,645 |
| 12/03/25 | 0.6755 | 0.686 | 0.6189 | 0.6492 | 1,074,942 |
| 11/03/25 | 0.81 | 0.8378 | 0.62 | 0.70 | 3,479,339 |
| 10/03/25 | 0.7647 | 1.34 | 0.735 | 0.92 | 73,934,071 |
| 07/03/25 | 0.6309 | 0.77 | 0.6006 | 0.6601 | 2,921,875 |
| 06/03/25 | 0.52 | 0.82 | 0.49 | 0.71 | 60,299,015 |
|
|
||||
|
|
||||
|
|